Severe asthma therapy
1 minute read
Animation showing the mechanical activation of TGF-beta protein
Recently licensed: A start-up has partnered with us to accelerate the development of a therapy for steroid-resistant asthma.
The technology
This is a treatment for severe, steroid-resistant asthma. It enhances steroid activity by selectively inhibiting signalling pathways downstream of TGFẞ.
Market need
Up to 10 per cent of asthma patients are resistant to inhaled corticosteroids. New drugs to control corticosteroid-resistant severe asthma is a major priority.
Technology status
Known compound PF670462 has achieved target validation. This compound enhances steroid activity, without evidence of autoimmune or cardiac toxicities.
Contact
Katrina Sorocos
Katrina.sorocos@unimelb.edu.au
Phone +61 3 8344 1919
Image: Animator - Andrew Lija/Composition - Alastair Stewart/Source - Boris Hinz 2015